14 reports of this reaction
1.5% of all PHENOBARBITAL SODIUM reports
#16 most reported adverse reaction
LOSS OF CONSCIOUSNESS is the #16 most commonly reported adverse reaction for PHENOBARBITAL SODIUM, manufactured by BPI Labs LLC. There are 14 FDA adverse event reports linking PHENOBARBITAL SODIUM to LOSS OF CONSCIOUSNESS. This represents approximately 1.5% of all 956 adverse event reports for this drug.
PHENOBARBITAL SODIUM has an overall safety score of 85 out of 100. Patients taking PHENOBARBITAL SODIUM who experience loss of consciousness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LOSS OF CONSCIOUSNESS is a less commonly reported adverse event for PHENOBARBITAL SODIUM, but still significant enough to appear in the safety profile.
In addition to loss of consciousness, the following adverse reactions have been reported for PHENOBARBITAL SODIUM:
The following drugs have also been linked to loss of consciousness in FDA adverse event reports:
LOSS OF CONSCIOUSNESS has been reported as an adverse event in 14 FDA reports for PHENOBARBITAL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
LOSS OF CONSCIOUSNESS accounts for approximately 1.5% of all adverse event reports for PHENOBARBITAL SODIUM, making it a notable side effect.
If you experience loss of consciousness while taking PHENOBARBITAL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.